Liabilities related to the sale of future royalties and development funding
258,570
227,488
220,068
-
Development derivative liability
-
-
0
121,251
Total current liabilities
1,512,513
1,349,475
1,466,349
1,555,477
Operating lease liabilities, net of current portion
210,495
218,025
225,087
223,421
Convertible debt
1,010,981
1,009,372
1,007,784
1,040,276
Liability related to the sale of future royalties, net of current portion
-
-
-
1,349,166
Liabilities related to the sale of future royalties and development funding, net of current portion
1,461,510
1,469,684
1,470,341
-
Development derivative liability, net of current portion
-
-
0
439,659
Other liabilities
9,152
7,611
7,594
9,769
Total liabilities
4,204,651
4,054,167
4,177,155
4,617,768
Common stock, 0.01 par value per share, 250,000 shares authorized 133,734 shares issued and outstanding as of june30, 2026 132,376 shares issued and outstanding as of december31, 2025
1,337
1,334
1,324
1,318
Additional paid-in capital
7,716,958
7,595,473
7,510,473
7,414,771
Accumulated other comprehensive loss
-32,138
-24,894
-20,097
-21,775
Accumulated deficit
-6,332,039
-6,496,533
-6,702,524
-7,160,420
Total stockholders' equity
1,354,118
1,075,380
789,176
233,894
Total liabilities and stockholders' equity
5,558,769
5,129,547
4,966,331
4,851,662
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
🚨 Price Alert: The stock price dropped by 23.04% after the earning call.